Servicio Andaluz de Salud
CONSEJERÍA DE SALUD
Hospital Regional Universitario Carlos Haya de Málaga

DI-044 EFFECTIVENESS OF THE COMBINATION SOFOSBUVIR AND DACLATASVIR FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION

Madera Pajín R., Asensi Díez R., Yunquera Romero L., del Río Valencia J.C., Muñoz Castillo I.
Hospital Regional Universitario Carlos Haya, Pharmacy, Málaga, Spain.

PURPOSE

To assess the effectiveness of the combination Sofosbuvir (SOF) and Daclatasvir (DCV) in HCV patients.

MATERIAL AND METHODS

Medical records of patients.

VARIABLES

- ✓Age and sex
- ✓Basal viral load (VL)
- ✓ Sustained virological response (SVR) week 12/24
- ✓ METAVIR score: F0-F4
- ✓Previous transplant
- ✓Previous treatments for HCV
- ✓ HIV co-infection
- ✓ Side effects
- ✓HCV genotype (G)
- ✓Drug interactions
- ✓Treatment duration

RESULTS

EPIDEMIOLOGICAL DATA	32 patients	43.75% women 57.9±7.8 years	**HIV CO-INFECTED**: 9.37% patients (2ITIAN+1 ITINN + IP/INI)
METAVIR SCORE	**F4**: 62.51% patients	**F3**: 15.62% patients **F2**: 12.5% patients	**F1**:3.12% patients **F0**:6.25% patients
GENOTYPE	**1**: 53.12% patients	**3**: 46.88% patients	
PREVIOUS TRASPLANT	Liver 28.12% patients	Kidney 3.13% patients	
BASAL VL (UI/ml)	>800.000: 46.87% patients	<800.000: 53.13% patients	
PREVIOUS TREATMENTS FOR VHC	43.75% patients	Ribavirina+ Peg-interferón α2a 78.58% patients	Ribavirina+ Peg-interferón α2a + Protease inhibitor 21.42 % patients



CONCLUSION

SVR12/24 rates achieved in our study confirm the results obtained in the study AI444-040 in G1:SVR12 rates of 100% in both treatments, naive patients and non responders. However, there are differences in the response in patients G3 compared with the study ALLY-3 (Our patients had rates of SVR12:naïve 100%(10/10) vs 90%(91/101) in ALLY-3study; non responders: SVR12:80%(4/5) vs 86%(44/51) in ALLY-3 study). In our study there was only one patient treated for 24 weeks, so no reliable conclusion can be drawn in SVR24 in G3.

ACKNOWLEDGEMENTS

No conflict of interest

maderapajinr@gmail.com

J05- ANTIVIRALS FOR SYSTEMIC USE